IPS HEART gets third FDA pediatric rare disease designation for ISX9-CPC
IPS HEART, a private cell therapy company developing treatments for Duchenne muscular dystrophy and heart failure, announced that it has received a third Rare Pediatric Drug Designation (RPDD) from the US Food and Drug Administration (FDA). The designation is for their product candidate, ISX9-CPC, which is being developed to treat cardiomyopathy associated with Danon disease, […]